Every logistics manager knows the trick: when one shipping route keeps failing, you don't just ship harder, you add a second carrier. Triple-negative breast cancer treatment has been stuck running a single supply line for years, and a Korean trial just tested what happens when you bolt a second truck onto the dock. The cargo, in this case, is a platinum drug called carboplatin.
The Population Problem
Let me frame this the way I frame everything, which is to say through a denominator. Triple-negative breast cancer (TNBC) makes up roughly 15% of breast cancers, but it punches well above its prevalence in the bad-outcomes column. It doesn't carry the three receptors (estrogen, progesterone, HER2) that the nicest targeted drugs love to grab onto, which means the entire elegant toolkit of modern breast cancer therapy mostly shrugs and walks away. What's left is good old chemotherapy: anthracyclines, then a taxane. Effective-ish. Not enough.
So the question on the table is the kind I find genuinely satisfying: if you add carboplatin to the regimen, does the survival curve actually move, or do you just give more people a rough month for no measurable population benefit?
The Trial, In Numbers
The PEARLY trial (the catchier alias of KCSG BR 15-1) enrolled 868 patients with stage II or III TNBC across 22 institutions in South Korea between 2016 and 2020. Solid sample size, multicenter, randomized - the kind of design that makes confounding variables sweat. Half got the standard doxorubicin-and-cyclophosphamide-then-taxane routine. The other half got the same thing with carboplatin riding shotgun alongside the taxane.
After tracking everyone for a median of 57 months (that's the part people forget matters most - a short follow-up can hide everything), the carboplatin arm came out ahead. Event-free survival hazard ratio of 0.67, confidence interval 0.49 to 0.92, P=0.012. In plain terms: the risk of a bad event dropped by about a third, and the interval didn't flirt with 1.0, so this isn't a statistical mirage.
Translated into the absolute numbers I actually trust: five-year event-free survival climbed from 75.1% to 82.3%. That's a 7.2 percentage-point gap. To save one additional person from an event over five years, you're treating somewhere in the neighborhood of 14 patients - which, for a disease this stubborn, is a respectable return on the loading dock.
The Asterisk Department
Here's where my professional caution kicks in, because every dataset has a fine-print section. Overall survival, invasive disease-free survival, and distant recurrence-free survival all leaned toward carboplatin, but none crossed the line into statistical significance. Directionally consistent trends are encouraging, but "trending in the right direction" and "proven" are separated by a chasm that has swallowed many a promising therapy. CALGB 40603 and the BrighTNess trial both showed carboplatin bumping up pathologic complete response rates, yet long-term survival benefits stayed frustratingly elusive. PEARLY is the trial that finally moved the primary survival endpoint, which is why it's a notable data point and not just another pCR press release.
And the cost of that second truck? Grade 3-or-higher adverse events jumped from 56.7% to 74.7%, driven mostly by the blood counts taking a beating. The encouraging footnote: quality-of-life measures didn't meaningfully deteriorate, which suggests the toxicity, while real, was the manageable kind rather than the life-derailing kind.
What This Means For The Denominator
If these results replicate and hold up over longer follow-up, carboplatin earns a stronger spot in the early TNBC playbook - particularly meaningful given that pembrolizumab (the KEYNOTE-522 regimen) is now reshaping this space too, and clinicians have to weigh how all these trucks share one dock. For a cancer subtype that disproportionately affects younger patients and those carrying BRCA mutations, every percentage point of five-year survival represents real people who get to keep showing up in next year's data. Which, from where I sit, is the whole point of counting them.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.
References
-
Kim GM, Jung KH, Jeung HC, et al. A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial. Annals of Oncology. 2026. DOI: 10.1016/j.annonc.2026.05.703. PMID: 42218963.
-
Sikov WM, Berry DA, Perou CM, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. DOI: 10.1200/JCO.21.01506. PMCID: PMC9015203.
-
Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology. 2022. DOI: 10.1016/j.annonc.2022.01.009.
-
Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis. PMCID: PMC12730687.